Rocket Pharmaceuticals (RCKT) Tops Q3 EPS by 6c

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q3 EPS of ($0.75), $0.06 better than the analyst estimate of ($0.81).

For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist